New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
09:10 EDTELGXEndologix presents data from PEVAR randomized trial
Endologix announced that data from the first prospective, multicenter, randomized clinical trial of a totally percutaneous approach, or PEVAR, to endovascular abdominal aortic aneurysm repair, or EVAR, was recently presented at two medical meetings. Key points from the trial include the primary trial endpoint was met, definitively demonstrating the non-inferiority of PEVAR using the ProGlide closure device to surgical EVAR, a 94% procedural technical success rate was achieved in a multicenter setting, mean procedure time was reduced in PEVAR patients by 34 minutes. Likewise, mean time to hemostasis was reduced following PEVAR by 13 minutes, PEVAR patients required significantly fewer concomitant procedures, favorable trending of PEVAR in several clinical utility outcomes including reduced anesthesia time, reduced blood loss and need for transfusion, shorter hospital length of stay, and less analgesics prescribed for groin pain, and the PEVAR non-inferiority to surgical EVAR persisted through the final 6-month follow-up.
News For ELGX From The Last 14 Days
Check below for free stories on ELGX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ELGX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use